Pancreas-associated antigen CA 19 - 9 may be used to monitor patients diagnosed with pancreatic carcinoma and to screen those at high risk (eg, those with hereditary pancreatitis; ≥ 2 first-degree family members with pancreatic cancer, Peutz-Jeghers syndrome, or BRCA2 or HNPCC mutations).